There’s light at the end of the tunnel. There’s also light at the beginning of the tunnel. And there’s light in the middle of ...

An Argentinian man with victims “up and down the coast of Queensland” posed as a massage therapist for his own sexual gratification, sexually assaulting one woman and taking thousands of photos and ...

Lexeo Therapeutics presents a compelling case for investors interested in the gene therapy space, with a focused pipeline targeting significant unmet needs and a proprietary vector technology. Despite ...

According to InvestingPro analysis, the company's stock appears slightly undervalued based on comprehensive Fair Value calculations, suggesting potential upside for investors. The company's focus on ...

According to InvestingPro analysis, the company's stock appears slightly undervalued based on comprehensive Fair Value calculations, suggesting potential upside for investors. The company's focus ...

Updates on the CF program are slated for mid-2025. These milestones represent potential catalysts for the company's stock and could provide further validation of FDMT's gene therapy platform. FDMT's ...

These milestones represent potential catalysts for the company's stock and could provide further validation of FDMT's gene therapy platform. FDMT's financial position reflects its status as a ...

The Novartis deal is one of the few positive boosts to PTC Therapeutics stock this year. Last month, the FDA granted accelerated approval to the company’s gene therapy Kebilidi for treating AADC ...

The company's primary focus is its CardiAMP cell therapy system, which is currently undergoing clinical ... analysts maintain a positive outlook on BioCardia's stock. The company's financial prospects ...

The NYSE announced that the staff of NYSE Regulation has determined to commence proceedings to delist the Class A common stock of ATI Physical Therapy (ATIP) from the NYSE. Trading in the Company ...